Currently, five distinct TKIs against BCR-ABL1 fusion are available for the treatment of the chronic phase of CML: imatinib, dasatinib, nilotinib, bosutinib, ponatinib and asciminib. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.